Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins Underscores Radiopharm’s commitment to developing ...

Sagimet Biosciences Inc.’s SGMT share price has surged by 7.11%, which has investors questioning if this is right time to ...

Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, an oral, selective fatty acid synthase (FASN) inhibitor, into Phase III trials for treating metabolic ...

These observations led to the discovery of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), the two key enzymes of fatty acid synthesis. His laboratory was the first to identify these ...

Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that ...

Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

and fatty acids is coupled to the generation of an electrochemical gradient across the inner mitochondrial membrane, which is harnessed by the ATP synthase to drive the formation of ATP.

Forestry waste can be turned into a high-value fatty acid, thanks to a bright red yeast engineered by University of Alberta researchers. Using wood-derived sugar as a feedstock, the strain ...